As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

A recent review and meta-analysis of semaglutide studies found that this drug can significantly reduce the risk of ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

The quick answer is, it's complicated. Number one, quality. Number three, delay of the product. because it's no longer ...

Research is still evolving to identify all the ways semaglutide can affect your overall health. Even so, it probably makes the biggest impact on your gut health, including digestion and metabolism, as ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...